References
- Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metabol 2013; 98(4):1443–1449.
- McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007; 91(4):455–458.
- Latvanlehto A, Fox MA, Sormunen R, Tu H, Oikarainen T, Koski A, et al. Muscle-derived collagen XIII regulates maturation of the skeletal neuromuscular junction. J Neurosci 2010; 30(37):12230–12241.
- Heikkinen A, Tu H, Pihlajaniemi T. Collagen XIII: a type II transmembrane protein with relevance to musculoskeletal tissues, microvessels and inflammation. Inter J Biochem Cell Biol 2012; 44(5):714–717.
- Tuomisto A, Sund M, Tahkola J, Latvanlehto A, Savolainen ER, Autio-Harmainen H, et al. A mutant collagen XIII alters intestinal expression of immune response genes and predisposes transgenic mice to develop B-cell lymphomas. Cancer Res 2008; 68(24):10324–10332.
- Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002; 12(10):855–860.
- Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L. Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Investig 2013; 36(6):444–449.
- El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 2004; 34(8):482–491.
- Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Amer J Ophthalmol 1995; 119(6):792–795.
- Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013; 9(12):724–734.
- Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Euro J Endocrinol 2002; 146(6):751–757.
- Abraham-Nordling M, Wallin G, Traisk F, Berg G, Calissendorff J, Hallengren B, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Euro J Endocrinol 2010; 163(4):651–657.
- Abraham-Nordling M, Wallin G, Lundell G, Torring O. Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves’ disease. Euro J Endocrinol 2007; 156(2):173–179.
- Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 2003; 24(6):802–835.
- Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. New Engl J Med 2008; 359(22):2313–2323.
- Vaisanen MR, Vaisanen T, Pihlajaniemi T. The shed ectodomain of type XIII collagen affects cell behaviour in a matrix-dependent manner. Biochem J 2004; 380(Pt 3):685–693.
- Gunji K, Kubota S, Swanson J, Kiljanski J, Bednarczuk T, Wengrowicz S, et al. Role of the eye muscles in thyroid eye disease: Identification of the principal autoantigens. Thyroid 1998; 8(6):553–556.
- Gopinath B, Ma G, Wall JR. Eye signs and serum eye muscle and collagen XIII antibodies in patients with transient and progressive thyroiditis. Thyroid 2007; 17(11):1123–1219.
- Gopinath B, Adams CL, Musselman R, Tani J, Wall JR. Antibodies against calsequestrin and type XIII collagen are good markers for chronic upper eyelid retraction. Ocul Immunol Inflam 2007; 15(2):81–88.
- Porter JD, Baker RS. Muscles of a different ‘color’: the unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Neurology 1996; 46(1):30–37.
- Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA 2001; 98(21):12062–12067.